• 1
    Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102(4 Part 1): 125968.
  • 2
    Shih YC, Barghout VE, Sandler RS, et al. Resource utilization associated with irritable bowel syndrome in the United States 1987–1997. Dig Dis Sci 2002; 47(8): 170515.
  • 3
    Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. McLean, VA: Degnon Associates, 2000.
  • 4
    Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001; 96(10): 290514.
  • 5
    Locke GR 3rd, Fett SL, Zinsmeister AR. Transition probabilities between functional gastrointestinal disorders in the community. Gastroenterology 2001; 120: A52(Abstract).
  • 6
    Thompson WG, Dotevall DA, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989; 2(2): 925.
  • 7
    Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107(4): 10409.
  • 8
    Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101(4): 92734.
  • 9
    Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992; 304(6819): 8790.
  • 10
    Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109(3): 67180.
  • 11
    Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998; 42(5): 6905.
  • 12
    Saito YA, Talley NJ, Melton LJ , Fett S, Zinsmeister AR, Locke GR. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Neurogastroenterol Motil 2003; 15(6): 68794.
  • 13
    El-Serag HB, Talley NJ. The prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 64354.
  • 14
    Stanghellini V, Tosetti C, Barbara G, et al. Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Am J Gastroenterol 2002; 97(11): 273843.
    Direct Link:
  • 15
    Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98(11): 24549.
    Direct Link:
  • 16
    Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 1997; 92(6): 9549.
  • 17
    Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999; 94(10): 292935.
    Direct Link:
  • 18
    Corsetti M, Caenepeel P, Fischler B, Janssens J, Tack J. Impact of co-existing irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol 2004; 99: 11529.
  • 19
    Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38(9): 156980.
  • 20
    Fischler B, Tack J, De Gucht V, et al. Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 2003; 124(4): 90310.
  • 21
    Talley NJ, Holtmann G, Agreus L, Jones M. Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. Am J Gastroenterol 2000; 95(6): 143947.
    Direct Link:
  • 22
    Eslick GD, Howell SC, Hammer J, Talley NJ. Empirically derived symptom sub-groups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome. A factor and cluster analysis of a patient sample. Aliment Pharmacol Ther 2004; 19(1): 13340.
  • 23
    Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med 1988; 108(6): 86579.
  • 24
    Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998; 10(5): 41521.
  • 25
    Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ 3rd. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992; 136(2): 16577.
  • 26
    Locke GR 3rd, Talley NJ. History of functional bowel disorders symptom turnover in the community. Gastroenterol 2004; 126(Suppl. 2): A369.
  • 27
    Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med 2001; 134(9 Part 2): 81522.
  • 28
    Camilleri M. Management of the irritable bowel syndrome [see comment]. Gastroenterology 2001; 120(3): 65268.
  • 29
    Heikkinen M, Farkkila M. What is the long-term outcome of the different subgroups of functional dyspepsia? Aliment Pharmacol Ther 2003; 18(2): 2239.
  • 30
    Kalantar JS, Locke GR 3rd, Talley NJ, et al. Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points. Aliment Pharmacol Ther 2003; 17(11): 138997.
  • 31
    Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ 3rd. Familial association in adults with functional gastrointestinal disorders. Mayo Clinic Proc 2000; 75(9): 90712.
  • 32
    Holtmann G, Siffert W, Haag S, et al. G-protein beta-3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004; 126: 9719.
  • 33
    Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha-2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53: 82937.
  • 34
    Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110(4): 103642.
  • 35
    Stanghellini V, Ghidini C, Maccarini MR, Paparo GF, Corinaldesi R, Barbara L. Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia. Gut 1992; 33(2): 18490.
  • 36
    Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115(6): 134652.
  • 37
    Thumshirn M, Camilleri M, Saslow SB, Williams DE, Burton DD, Hanson RB. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut 1999; 44(1): 5564.
  • 38
    Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds [see comment]. Gastroenterology 2002; 122(7): 17717.
  • 39
    Kellow JE, Miller LJ, Phillips SF, Haddad AC, Zinsmeister AR, Charboneau JW. Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide. Am J Physiol 1987; 252(3 Part 1): G34556.
  • 40
    Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11(1): 315.
  • 41
    Camilleri M. Drugs targeting functional bowel disorders: lessons from drug trials. Curr Opin Pharmacol 2002; 2(6): 68490.
  • 42
    Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992; 102(1): 1028.
  • 43
    Waldron B, Cullen PT, Kumar R, et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32(3): 24651.
  • 44
    Lorena SL, De Souza Almeida JR, Mesquita MA. Orocecal transit time in patients with functional dyspepsia. J Clin Gastroenterol 2002; 35(1): 214.
  • 45
    Bonapace ES, Maurer AH, Davidoff S, Krevsky B, Fisher RS, Parkman HP. Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. Am J Gastroenterol 2000; 95(10): 283847.
    Direct Link:
  • 46
    Chitkara DK, Delgado-Aros S, Bredenoord AJ, et al. Functional dyspepsia, upper gastrointestinal symptoms, and transit in children. J Pediatrics 2003; 143(5): 60913.
  • 47
    Nabar AA, Bhatia SJ, Abraham P, Ravi P, Mistry FP. Total and segmental colonic transit time in non-ulcer dyspepsia. Indian J Gastroenterol 1995; 14(4): 1313.
  • 48
    Tjeerdsma HC, Smout AJ, Akkermans LM. Voluntary suppression of defecation delays gastric emptying. Dig Dis Sci 1993; 38(5): 8326.
  • 49
    Snape WJ Jr, Matarazzo SA, Cohen S. Effect of eating and gastrointestinal hormones on human colonic myoelectrical and motor activity. Gastroenterology 1978; 75(3): 3738.
  • 50
    Cote F, Pare P, Friede J. Physiological effect of cholecystokinin on gastric emptying of liquid in functional dyspepsia. Am J Gastroenterol 1995; 90(11): 20069.
  • 51
    Feinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48(3): 34755.
  • 52
    Coffin B, Fossati S, Flourie B, et al. Regional effects of cholecystokinin octapeptide on colonic phasic and tonic motility in healthy humans. Am J Physiol 1999; 276(3 Part 1): G76772.
  • 53
    Niederau C, Faber S, Karaus M. Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome. Gastroenterology 1992; 102(6): 188998.
  • 54
    Renny A, Snape WJ Jr, Sun EA, London R, Cohen S. Role of cholecystokinin in the gastrocolonic response to a fat meal. Gastroenterology 1983; 85(1): 1721.
  • 55
    Mangel AW, Brazer SR, Smith JW, Fitz JG, Taylor IL. Inhibition of colonic motility by cholecystokinin. Ann Med 1992; 24(5): 3412.
  • 56
    Harvey RF, Read AE. Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable bowel syndrome. Lancet 1973; 1(7793): 13.
  • 57
    Raybould HE. Visceral perception: sensory transduction in visceral afferents and nutrients. Gut 2002; 51(Suppl. 1): i114.
  • 58
    Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome [erratum appears in Gastroenterology 1997; 113(3): 1054]. Gastroenterology 1995; 109(1): 40–52.
  • 59
    Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology 1998; 115(5): 126371.
  • 60
    Mayer EA, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002; 122(7): 203248.
  • 61
    Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980; 25(6): 40413.
  • 62
    Poitras P, Riberdy Poitras M, Plourde V, Boivin M, Verrier P. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 2002; 47(4): 91420.
  • 63
    Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40(8): 160713.
  • 64
    Mearin F, Cucala M, Azpiroz F, Malagelada JR. The origin of symptoms on the brain–gut axis in functional dyspepsia. Gastroenterology 1991; 101(4): 9991006.
  • 65
    Coffin B, Azpiroz F, Guarner F, Malagelada JR. Selective gastric hypersensitivity and reflex hyporeactivity in functional dyspepsia. Gastroenterology 1994; 107(5): 134551.
  • 66
    Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000; 118(5): 8428.
  • 67
    Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C. Gastric distention correlates with activation of multiple cortical and subcortical regions. Gastroenterology 2001; 120(2): 36976.
  • 68
    Talley NJ. Dyspepsia. Gastroenterology 2003; 125(4): 121926.
  • 69
    Saslow SB, Thumshirn M, Camilleri M, et al. Influence of H. pylori infection on gastric motor and sensory function in asymptomatic volunteers. Dig Dis Sci 1998; 43(2): 25864.
  • 70
    Tucci A, Corinaldesi R, Stanghellini V, et al. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992; 103(3): 76874.
  • 71
    Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122(7): 173847.
  • 72
    Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhea [see comment]. Lancet 1996; 347(8995): 1503.
  • 73
    Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 1997; 113(4): 122432.
  • 74
    Neal KR, Barker L, Spiller RC. Prognosis in post–infective irritable bowel syndrome: a six year follow up study [see comment]. Gut 2002; 51(3): 4103.
  • 75
    Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999; 45(Suppl. 2): II2530.
  • 76
    Talley NJ, Phillips SF, Bruce B, et al. Relation among personality and symptoms in nonulcer dyspepsia and the irritable bowel syndrome. Gastroenterology 1990; 99(2): 32733.
  • 77
    Delgado-Aros S, Cremonini F, Talley NJ. Treatment of Functional Dyspepsia. Curr Treat Options Gastroenterol 2004; 7: 12131.
  • 78
    Olden KW. Therapy for irritable bowel syndrome. N Engl J Med 2004; 350: 12613.
  • 79
    Tack J, Coulie B, Wilmer A, Andrioli A, Janssens J. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46(4): 46873.
  • 80
    Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118(3): 4638.
  • 81
    Dave B, Rubin W. Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. Dig Dis Sci 1999; 44(9): 18938.
  • 82
    De Schepper H, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16: 38394.
  • 83
    Cremonini F, Delgado-Aros S, Talley NJ. Functional dyspepsia: drugs for new (and old) therapeutic targets. Best Pract Clin Gastroenterol Hepatol 2004; 18: 71733.
  • 84
    Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108(1): 6572.